Literature DB >> 28386908

Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients.

Raffaella Meazza1, Michela Falco2, Stefania Marcenaro2, Fabrizio Loiacono1,2, Paolo Canevali2, Francesca Bellora3, Claudia Tuberosa1,3, Franco Locatelli4,5, Concetta Micalizzi6, Alessandro Moretta3, Maria C Mingari1,3, Lorenzo Moretta7, Maurizio Aricò8, Cristina Bottino2,3, Daniela Pende1.   

Abstract

X-linked lymphoproliferative disease 1 (XLP1) is an inherited immunodeficiency, caused by mutations in SH2D1A encoding Signaling Lymphocyte Activation Molecule (SLAM)-associated protein (SAP). In XLP1, 2B4, upon engagement with CD48, has inhibitory instead of activating function. This causes a selective inability of cytotoxic effectors to kill EBV-infected cells, with dramatic clinical sequelae. Here, we investigated the NK cell education in XLP1, upon characterization of killer Ig-like receptor (KIR)/KIR-L genotype and phenotypic repertoire of self-HLA class I specific inhibitory NK receptors (self-iNKRs). We also analyzed NK-cell cytotoxicity against CD48+ or CD48- KIR-ligand matched or autologous hematopoietic cells in XLP1 patients and healthy controls. XLP1 NK cells may show a defective phenotypic repertoire with substantial proportion of cells lacking self-iNKR. These NK cells are cytotoxic and the inhibitory 2B4/CD48 pathway plays a major role to prevent killing of CD48+ EBV-transformed B cells and M1 macrophages. Importantly, self-iNKR defective NK cells kill CD48- targets, such as mature DCs. Self-iNKR- NK cells in XLP1 patients are functional even in resting conditions, suggesting a role of the inhibitory 2B4/CD48 pathway in the education process during NK-cell maturation. Killing of autologous mature DC by self-iNKR defective XLP1 NK cells may impair adaptive responses, further exacerbating the patients' immune defect.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  2B4; CD48; HLA class I; KIR; NK cells; NK receptors; NK-cell education; SAP; SLAM; XLP1

Mesh:

Substances:

Year:  2017        PMID: 28386908     DOI: 10.1002/eji.201646885

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Killer-cell immunoglobulin-like receptors on the cusp of modern immunogenetics.

Authors:  Francesco Colucci; James Traherne
Journal:  Immunology       Date:  2017-09-12       Impact factor: 7.397

Review 2.  Natural killer cells in liver diseases.

Authors:  Meijuan Zheng; Haoyu Sun; Zhigang Tian
Journal:  Front Med       Date:  2018-04-19       Impact factor: 4.592

Review 3.  The Broad Spectrum of Human Natural Killer Cell Diversity.

Authors:  Aharon G Freud; Bethany L Mundy-Bosse; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

Review 4.  Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Authors:  Daniela Pende; Michela Falco; Massimo Vitale; Claudia Cantoni; Chiara Vitale; Enrico Munari; Alice Bertaina; Francesca Moretta; Genny Del Zotto; Gabriella Pietra; Maria Cristina Mingari; Franco Locatelli; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

Review 5.  An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Authors:  Massimo Vitale; Claudia Cantoni; Mariella Della Chiesa; Guido Ferlazzo; Simona Carlomagno; Daniela Pende; Michela Falco; Annamaria Pessino; Letizia Muccio; Andrea De Maria; Emanuela Marcenaro; Lorenzo Moretta; Simona Sivori
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 6.  On the Way to Become a Natural Killer Cell.

Authors:  Clara Di Vito; Joanna Mikulak; Domenico Mavilio
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 7.  Human NK cells, their receptors and function.

Authors:  Linda Quatrini; Mariella Della Chiesa; Simona Sivori; Maria Cristina Mingari; Daniela Pende; Lorenzo Moretta
Journal:  Eur J Immunol       Date:  2021-05-10       Impact factor: 6.688

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.